Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis: Type 1 diabetes results from T cell mediated destruction of beta cells. We conducted a trial of antithymocyte globulin (ATG) in new-onset type 1 diabetes (the Study of Thymoglobulin to ARrest T1D [START] trial). Our goal was to evaluate the longer-term safety and efficacy of ATG in preserving islet function at 2 years. Methods: A multicentre, randomised, double-blind, placebo-controlled trial of 6.5 mg/kg ATG (Thymoglobulin) vs placebo in patients with new-onset type 1 diabetes was conducted at seven university medical centres and one Children’s Hospital in the USA. The site-stratified randomisation scheme was computer generated at the data coordinating centre using permuted-blocks of size 3 or 6. Eligible participants were between the ages of 12 and 35, and enrolled within 100 days from diagnosis. Subjects were randomised to 6.5 mg/kg ATG (thymoglobulin) vs placebo in a 2:1 ratio. Participants were blinded, and the study design included two sequential patient-care teams: an unblinded study-drug administration team (for the first 8 weeks), and a blinded diabetes management team (for the remainder of the study). Endpoints assessed at 24 months included meal-stimulated C-peptide AUC, safety and immunological responses. Results: Fifty-eight patients were enrolled; at 2 years, 35 assigned to ATG and 16 to placebo completed the study. The pre-specified endpoints were not met. In post hoc analyses, older patients (age 22–35 years) in the ATG group had significantly greater C-peptide AUCs at 24 months than placebo patients. Using complete preservation of baseline C-peptide at 24 months as threshold, nine of 35 ATG-treated participants (vs 2/16 placebo participants) were classified as responders; nine of 11 responders (67%) were older. All participants reported at least one adverse event (AE), with 1,148 events in the 38 ATG participants vs 415 in the 20 placebo participants; a comparable number of infections were noted in the ATG and placebo groups, with no opportunistic infections nor difficulty clearing infections in either group. Circulating T cell subsets depleted by ATG partially reconstituted, but regulatory, naive and central memory subsets remained significantly depleted at 24 months. Beta cell autoantibodies did not change over the 24 months in the ATG-treated or placebo participants. At 12 months, ATG-treated participants had similar humoral immune responses to tetanus and HepA vaccines as placebo-treated participants, and no increased infections. Conclusions/interpretation: A brief course of ATG substantially depleted T cell subsets, including regulatory cells, but did not preserve islet function 24 months later in the majority of patients with new-onset type 1 diabetes. ATG preserved C-peptide secretion in older participants, which may warrant further study. Trial registration: ClinicalTrials.gov NCT00515099 Public data repository: START datasets are available in TrialShare www.itntrialshare.org Funding: National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The trial was conducted by the Immune Tolerance Network (ITN).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 1×
“Therapies directed against T cells can alter the course of disease, but to date have had only initial limited success in beta cell preservation [1 – 9].”
Self-citationMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093 · cited 1×
“Therapies directed against T cells can alter the course of disease, but to date have had only initial limited success in beta cell preservation [1–9].”
Self-citationSherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493 · cited 1×
“Therapies directed against T cells can alter the course of disease, but to date have had only initial limited success in beta cell preservation [1–9].”
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Feutren, G., Assan, R., Karsenty, G., Du Rostu, H., Sirmai, J., Papoz, L., Vialettes, B., Vexiau, P., Rodier, M., Lallemand, A., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91943-4 · Cited by 448
Bellin, M. D., Barton, F. B., Heitman, A., Harmon, J. V., Kandaswamy, R., Balamurugan, A. N., Sutherland, D. E. R., Alejandro, R., & Hering, B. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03977.x · Cited by 350
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Self-citationHaller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Rosenthal, S. M., Shuster, J. J., Zou, B., Brusko, T. M., Hulme, M. A., Wasserfall, C. H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78492 · Cited by 167
Self-citationThe Canadian-European Randomized Control Trial Group (1988) · Diabetes · doi:10.2337/diab.37.11.1574 · Cited by 164
D’Addio, F., Valderrama Vasquez, A., Ben Nasr, M., Franek, E., Zhu, D., Li, L., Ning, G., Snarski, E., & Fiorina, P. (2014) · Diabetes · doi:10.2337/db14-0295 · Cited by 160 · cited 1×
“This approach leads to better efficacy than any other immune intervention evaluated to date, but at the cost of significant short-and long-term morbidity [21].”
Cited by
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342
Inclusion body myositis: clinical features and pathogenesis
Greenberg, S. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0186-x · Cited by 273
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
Quattrin, T., Haller, M. J., Steck, A. K., Felner, E. I., Li, Y., Xia, Y., Leu, J. H., Zoka, R., Hedrick, J. A., Rigby, M. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006136 · Cited by 255
Self-citationKuric, E., Seiron, P., Krogvold, L., Edwin, B., Buanes, T., Hanssen, K. F., Skog, O., Dahl-Jørgensen, K., & Korsgren, O. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.11.002 · Cited by 80
Haller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Perry, D. J., Schultz, A. R., Hulme, M. A., Shuster, J. J., Zou, B., Wasserfall, C. H., et al. (2016) · Diabetes · doi:10.2337/db16-0823 · Cited by 70
Self-citation
Metadata
- Authors
- Gitelman, S. E., Gottlieb, P. A., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M., Moore, W. V., Pinckney, A., Keyes-Elstein, L., Harris, K. M., Kanaparthi, S., Phippard, D., Ding, L., Bluestone, J. A., Ehlers, M. R., & the ITN START Study Team
- Venue
- Diabetologia
- Published
- 2016-04-06
- Volume
- 59
- Issue
- 6
- Pages
- 1153-1161
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2323393837
- Cited by
- 90
- References
- 12
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.